SCHEMBL22987478

SCHEMBL22987478

COc1cccc(-c2nc3c4c(F)cccc4nc(Cl)n3n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CSNK1D P48730 1/20 0.41
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 4/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2B6 P20813 2/20 0.41
AHR P35869 2/20 0.41
NR1I3 Q14994 2/20 0.41
VDR P11473 1/20 0.41
MAOB P27338 1/20 0.41
ADORA2A P29274 5/20 0.41
ADORA3 P0DMS8 3/20 0.41
CLK4 Q9HAZ1 3/20 0.40
CYP2D6 P10635 3/20 0.40
USP2 O75604 2/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22987866 0.88 NR1H2 (0.46) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL29646448 0.83 MAPT (0.57) NR1H2NR1H3MAPTSMN1; SMN2CYP1A2
SCHEMBL22979197 0.83 MAPT (0.57) NR1H2NR1H3MAPTSMN1; SMN2CYP1A2
SCHEMBL22987471 0.81 MAPT (0.45) NR1H2NR1H3MAPTSMN1; SMN2CYP1A2
SCHEMBL22987875 0.81 MAPT (0.45) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL29450042 0.80 TOP1 (0.51) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL31150098 0.78 CSNK1D (0.43) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL22987485 0.78 MAPT (0.52) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL22987469 0.78 MAPT (0.52) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D
SCHEMBL29648828 0.77 MAPT (0.42) NR1H2NR1H3MAPTSMN1; SMN2CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 NR1H2 296/4885NR1H3 422/4885MAPT 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.